Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy.

ABSTRACT:

Background

The objective of this study was to characterize the clinicopathologic features of sicca syndrome associated with immune checkpoint inhibitor (ICI) therapy.

Subjects, materials, and methods

Consecutive patients with new or worsening xerostomia in the setting of ICI treatment for benign or malignant neoplastic disease were evaluated, including labial salivary gland biopsy (LSGB).

Results

Twenty patients (14 male; median age 57 years) had metastatic melanoma (n = 10), metastatic carcinoma (n = 6), or recurrent respiratory papillomatosis (n = 4) and were being treated with avelumab (n = 8), nivolumab (n = 5), pembrolizumab (n = 4), nivolumab/ipilimumab (n = 2), and M7824, a biologic targeting programmed cell deat

SUBMITTER: Warner BM 

PROVIDER: S-EPMC6738284 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature